secwatch.observer — SEC 8-K summary
======================================

Issuer:     Y-mAbs Therapeutics, Inc. (—)
CIK:        0001722964
Form:       8-K
Filed at:   2025-09-16T23:59:59+00:00
Accession:  0001104659-25-090232
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Y-mAbs acquired by Perseus BidCo US; tender offer completed at $8.60/share, ~$413M total
--------------------------------------------------------------------------------

- Approximately 39.8M shares (~87.22%) tendered; Purchaser accepted all validly tendered shares.
- Merger closed Sep 16; each outstanding share (except excluded) converted to $8.60 cash.
- Aggregate consideration ~$413M funded via cash on hand and short-term financing.
- Shares to be delisted from Nasdaq; company will file Form 15 to suspend reporting obligations.
- All prior directors and officers resigned; new board and officers appointed (Vanessa Wolfeler, Robert Duffield, Daniel Dolan).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1722964/000110465925090232/0001104659-25-090232-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1722964/000110465925090232/tm2525998d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-090232

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer